3i Nabs Ex-Morgan Stanley Healthcare Banking Chief

John Moore Jr. has joined 3i North America as a partner, with a responsibility for the group’s healthcare strategy. He previously was with Morgan Stanley as a managing director and global head of healthcare I-banking.

PRESS RELEASE

3i, an international leader in private equity, has appointed John J. Moore, Jr. as Partner 3i North America. This appointment underlines 3i’s commitment to the North American market and demonstrates the continued growth of 3i’s global healthcare investing strategy. 

John will be responsible for 3i’s healthcare investment strategy across North America. He joins a team of more than 20 3i healthcare professionals operating across North America, Europe and Asia. 3i’s global healthcare team has invested approximately $2bn in over 36 healthcare companies since 2001. John’s appointment completes 3i’s global healthcare leadership team, which is led by Alan Mackay in London. 

John brings extensive healthcare experience to 3i. He joins after 15 years with Morgan Stanley where as a Managing Director and the Global Head of Healthcare Investment Banking, he was responsible for all aspects of Morgan Stanley’s healthcare banking efforts around the world.

“We are pleased to have John join 3i as we continue our expansion in North America,” said Ken Hanau, Partner, Head of 3i North America. “Healthcare is a major area of focus for 3i and with his expertise, knowledge and enthusiasm; John will be a great addition to the team.”

Alan Mackay, Global Head of 3i Healthcare added: “The addition of John to 3i’s team accelerates our focus on healthcare private equity and our global perspective and local networks allow 3i to invest strategically to further our growth while providing unique and valuable insights to our portfolio companies. ”

3i’s recent healthcare global investments include: minority investment in Quintiles, world’s leading provider of clinical research outsourcing (CRO) solutions, offering clinical drug development services to pharma and biotech clients; €140m (around US$223m) for a minority stake in Labco, a leading pan European medical diagnostics network and the buyout of Singapore based LHi Technology, a leading designer and manufacturer of medical cables.